NuVasive, Inc. (NASDAQ:NUVA)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $51.04 and last traded at $50.85, with a volume of 1,544,260 shares. The stock had previously closed at $53.73.
Several equities analysts recently commented on the company. Royal Bank Of Canada reissued a “buy” rating and set a $75.00 price target on shares of NuVasive in a research report on Tuesday. BTIG Research restated a “buy” rating and set a $74.00 price objective (down from $82.00) on shares of NuVasive in a report on Wednesday, October 4th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective (down from $81.00) on shares of NuVasive in a report on Friday, October 6th. Gabelli restated a “buy” rating on shares of NuVasive in a report on Monday, July 31st. Finally, Piper Jaffray Companies restated a “buy” rating and set a $90.00 price objective on shares of NuVasive in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $77.92.
The firm’s 50 day moving average price is $58.22 and its 200 day moving average price is $69.85. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of 81.48 and a beta of 1.03.
In other news, Director Lesley H. Howe sold 3,970 shares of the stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $64.64, for a total value of $256,620.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Gregory T. Lucier bought 2,000 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was bought at an average cost of $61.52 per share, with a total value of $123,040.00. The disclosure for this purchase can be found here. Insiders acquired a total of 14,850 shares of company stock valued at $955,598 in the last quarter. Corporate insiders own 1.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Navellier & Associates Inc raised its holdings in shares of NuVasive by 5.2% in the 2nd quarter. Navellier & Associates Inc now owns 74,387 shares of the medical device company’s stock worth $5,722,000 after buying an additional 3,696 shares in the last quarter. Broadfin Capital LLC acquired a new position in shares of NuVasive in the 2nd quarter worth approximately $4,300,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of NuVasive in the 2nd quarter worth approximately $501,000. Public Employees Retirement System of Ohio raised its holdings in shares of NuVasive by 68.3% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 115,372 shares of the medical device company’s stock worth $8,874,000 after buying an additional 46,805 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its holdings in shares of NuVasive by 4.3% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 70,657 shares of the medical device company’s stock worth $5,435,000 after buying an additional 2,922 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “NuVasive, Inc. (NUVA) Reaches New 12-Month Low at $51.04” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/10/11/nuvasive-inc-nuva-reaches-new-12-month-low-at-51-04.html.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
What are top analysts saying about NuVasive Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NuVasive Inc. and related companies.